E-ISSN: 1305-3612
Modified transarterial chemoembolization with locoregional administration of sorafenib for treating hepatocellular carcinoma: feasibility, efficacy, and safety in the VX-2 rabbit liver tumor model
PDF
Cite
Share
Request
Interventional Radiology - Original Article
VOLUME: 22 ISSUE: 4
P: 378-384
July 2016

Modified transarterial chemoembolization with locoregional administration of sorafenib for treating hepatocellular carcinoma: feasibility, efficacy, and safety in the VX-2 rabbit liver tumor model

Diagn Interv Radiol 2016;22(4):378-384
DOI: 10.5152/dir.2016.15462
Max Seidensticker 1
Sebastian Streit 1
Norbert Nass 2
Christian Wybranski 1
Julian Jürgens 1
Jan Brauner 1
Nadine Schulz 1
Thomas Kalinski 2
Ricarda Seidensticker 1
Benjamin Garlipp 3
Ingo Steffen 1
Jens Ricke 1
Oliver Dudeck 1
1. Klinik für Radiologie und Nuklearmedizin, Universitätsklinik Magdeburg, Magdeburg, Germany
2. Institut für Pathologie, Universitätsklinik Magdeburg, Magdeburg, Germany
3. Klinik für Allgemein, Viszeral- und Gefäßchirurgie, Universitätsklinik Magdeburg, Magdeburg, Germany
No information available.
No information available
Received Date: 20.10.2015
Accepted Date: 09.12.2015
PDF
Cite
Share
Request

ABSTRACT

PURPOSE:

We aimed to assess the feasibility, efficacy and safety of a local application of sorafenib within a conventional transarterial chemoembolization in the VX-2 tumor-bearing rabbit model.

METHODS:

VX-2 tumors were induced in the left liver lobe of 10 New Zealand White rabbits. After two weeks, growth was verified by contrast-enhanced computed tomography (CT). Five rabbits were treated by transarterial chemoembolization using an emulsion of sorafenib and ethiodized oil (referred to as SORATACE; n=5). Rabbits receiving oral sorafenib for two weeks (n=2) and untreated rabbits (n=3) served as controls. After two weeks, contrast-enhanced CT was performed, followed by animal necropsy.

RESULTS:

The change in tumor diameter between baseline and follow-up was significantly different in the SORATACE group compared with the other groups; tumor shrinkage was observed in the SORATACE group only (P = 0.016). In both control groups, preserved hypervascularity was seen in the follow-up CT in all but one tumor. All tumors in the SORATACE group were devascularized in the follow-up CT. Importantly, substantial parenchymal damage in nontargeted areas of the tumor-bearing liver lobe was seen in rabbits treated with SORATACE.

CONCLUSION:

SORATACE demonstrated high efficacy in the treatment of experimental VX-2 liver tumors but was also associated with substantial liver parenchymal toxicity.